ESMO Preceptorship on Prostate Cancer 2014

Oncology Meeting Resources

16 Oct - 17 Oct, Lugano, Switzerland

ESMO Preceptorship on Prostate Cancer

On this page, you may download the PDFs of presentations given at the Preceptorship on Prostate Cancer 2014 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Search Meeting Resources by Keyword

Useful links

Presenter Presentation title Session title
Alan Horwich Welcome from ESMO, objectives and scientific introduction Opening and Welcome session
Ferran Algaba Diagnosis, pathology and prognosis, including variant pathology Screening, diagnosis and staging session
Theo M. de Reijke Screening and staging Screening, diagnosis and staging session
Ferran Algaba Prostate biomarkers, molecular pathology and genetics Screening, diagnosis and staging session
Thomas Wiegel Role of radiotherapy Localised prostate cancer session
Theo M. de Reijke Role of surgery Localised prostate cancer session
Zafeiris Zafereiou “A case of prostate cancer” Localised prostate cancer session
Caroline Ferreira Extreme hypofractionation in prostate cancer clinical case Localised prostate cancer session
Alan Horwich Active surveillance in early prostate cancer Localised prostate cancer session
Theo M. de Reijke Presentation with lymphadenopathy Advanced prostate cancer session
Theo M. de Reijke Urinary obstruction Advanced prostate cancer session
Gedske Daugaard Value and role of PSA as a tumor marker of response/relapse Advanced prostate cancer session
Thomas Wiegel Locally-advanced prostate cancer should be treated with radiotherapy and hormone deprivation Advanced prostate cancer session
Theo M. de Reijke Locally-advanced prostate cancer should not be treated with radiotherapy and hormone deprivation Advanced prostate cancer session
Antonello Veccia Abiraterone withdrawal syndrome in metastatic castration resistant prostate cancer Initial and second-line hormone therapies session